TY - JOUR
T1 - Randomised clinical trial
T2 - the effectiveness of Gaviscon Advance vs non-alginate antacid in suppression of acid pocket and post-prandial reflux in obese individuals after late-night supper
AU - Deraman, Mohd Adli
AU - Abdul Hafidz, Muhammad Ilham
AU - Lawenko, Rona Marie
AU - Ma, Zheng Feei
AU - Wong, Mung Seong
AU - Coyle, Cathal
AU - Lee, Yeong Yeh
N1 - Funding Information:
The study was funded by Reckitt Benckiser (M) Sdn. Bhd. The funder had no role in study design, data collection and analysis and decision to publish. Declaration of personal interests: Yeong Yeh Lee has received research funding from Reckitt Benckiser and Morinaga Milk Industry, and has served as speaker or consultant or advisory board member for Reckitt Benckiser, Takeda, Servier and Danone-Dumex. Other authors did not have personal interests. Declaration of funding interests: This study was funded in full by Reckitt Benckiser (M) Sdn Bhd.
Funding Information:
: Yeong Yeh Lee has received research funding from Reckitt Benckiser and Morinaga Milk Industry, and has served as speaker or consultant or advisory board member for Reckitt Benckiser, Takeda, Servier and Danone‐Dumex. Other authors did not have personal interests. Declaration of personal interests
Funding Information:
The study was funded by Reckitt Benckiser (M) Sdn. Bhd. The funder had no role in study design, data collection and analysis and decision to publish.
Publisher Copyright:
©2020 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Background: Late-night supper increases the risk of postprandial reflux from the acid pocket especially in obesity. An alginate-based, raft-forming medication may be useful for obese patients with GERD. Aims: To compare the efficacy of Gaviscon Advance (Reckitt Benckiser, UK) and a non-alginate antacid in post-supper suppression of the acid pocket and post-prandial reflux among obese participants. Methods: Participants underwent 48 h wireless and probe-based pH-metry recording of the acid pocket and lower oesophagus, respectively, and were randomised to single post-supper (10 pm) dose of either Gaviscon Advance or a non-alginate antacid on the second night. Primary outcomes were suppression of median pH of acid pocket and lower oesophagus, measured every 10-minutes post-supper for 1 h. Secondary outcomes were suppression of % time pH < 4 at lower oesophagus and improvement in frequency and visual analogue score (VAS) of regurgitation. Results: Of the 81 screened participants, 55 were excluded and 26 (mean age 33.5 years, males 77.8% and BMI 32.8 kg/m2) were randomised to Gaviscon Advance (n = 13) or antacid (n = 13). Median pH of the acid pocket but not the lower oesophagus was suppressed with Gaviscon Advance vs antacid (all P < 0.04) Gaviscon Advance but not antacid significantly reduced in % time pH < 4, symptom frequency and VAS on day 2 vs day 1 (all P < 0.05). Conclusions: Among obese individuals, Gaviscon Advance was superior to a non-alginate antacid in post-supper suppression of the acid pocket. (Clinical trial registration unique identifier: NCT03516188).
AB - Background: Late-night supper increases the risk of postprandial reflux from the acid pocket especially in obesity. An alginate-based, raft-forming medication may be useful for obese patients with GERD. Aims: To compare the efficacy of Gaviscon Advance (Reckitt Benckiser, UK) and a non-alginate antacid in post-supper suppression of the acid pocket and post-prandial reflux among obese participants. Methods: Participants underwent 48 h wireless and probe-based pH-metry recording of the acid pocket and lower oesophagus, respectively, and were randomised to single post-supper (10 pm) dose of either Gaviscon Advance or a non-alginate antacid on the second night. Primary outcomes were suppression of median pH of acid pocket and lower oesophagus, measured every 10-minutes post-supper for 1 h. Secondary outcomes were suppression of % time pH < 4 at lower oesophagus and improvement in frequency and visual analogue score (VAS) of regurgitation. Results: Of the 81 screened participants, 55 were excluded and 26 (mean age 33.5 years, males 77.8% and BMI 32.8 kg/m2) were randomised to Gaviscon Advance (n = 13) or antacid (n = 13). Median pH of the acid pocket but not the lower oesophagus was suppressed with Gaviscon Advance vs antacid (all P < 0.04) Gaviscon Advance but not antacid significantly reduced in % time pH < 4, symptom frequency and VAS on day 2 vs day 1 (all P < 0.05). Conclusions: Among obese individuals, Gaviscon Advance was superior to a non-alginate antacid in post-supper suppression of the acid pocket. (Clinical trial registration unique identifier: NCT03516188).
UR - http://www.scopus.com/inward/record.url?scp=85084007878&partnerID=8YFLogxK
U2 - 10.1111/apt.15746
DO - 10.1111/apt.15746
M3 - Article
C2 - 32343001
AN - SCOPUS:85084007878
SN - 0269-2813
VL - 51
SP - 1014
EP - 1021
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
IS - 11
ER -